Buy P&G Health Ltd For Target Rs.6,555 - ICICI Direct
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Mixed quarter but decent overall yearly performance...
About the stock: Procter & Gamble Health Limited is a leading Pharma cum OTC company with key focus on Vitamins Minerals Supplement (VMS) category
* It has legacy brands in the VMS category like Neurobion, Polybion, Evion (all vitamins), Livogen (iron supplement), Nasivion (nasal decongestant), Seven Seas (vitamin- substitute for malt based health drinks)
* This company was earlier known as Merck Limited and was a part of Merck KGaA, Germany. In 2018 it (as a Consumer Health Business) was acquired by P&G.
Q4FY21 Results: PGHL reported mixed set of Q4FY21 results.
* Sales were up 41.9% YoY to | 285.4 crore
* EBITDA in Q4FY21 was at | 48 crore, down 8.8% YoY with margins at 17%
* Consequent PAT was at | 33.9 crore (down 30.6% YoY)
What should investors do? PGHL share price has grown by ~7.5x over the past five years (from ~| 728 in Aug 2016 to ~| 5530 levels in Aug 2021).
* We change our rating from HOLD to BUY rating on the stock given the good overall FY21 performance and decent growth potential for its power brands
Target Price and Valuation: We value PGHL at | 6555 i.e. 45x P/E on FY23E EPS
Key triggers for future price performance:
* P&G’s strong distribution channel and strong brand recall are likely catalysts for future growth
* MNC pharma traits like strong brand stickiness, growth, earnings visibility, consistency (despite quarterly fluctuations) in performances, strong b/s
* Key differentiator for PGHL is that its core category is VMS, which, as a therapeutic category, is likely to be rediscovered due to increased awareness post the current pandemic.
Alternate Stock Idea: Apart from PGHL, in our healthcare coverage we like Abbott.
* Abbott India is one of the fastest growing listed MNC pharma companies. It has outperformed the industry on a consistent basis in women’s health, GI, metabolic, pain, CNS among others
* BUY with target price of | 20360
To Read Complete Report & Disclaimer Click Here
https://secure.icicidirect.com/Content/StaticData/Disclaimer.html
Above views are of the author and not of the website kindly read disclaimer
